Second-line Hycamtin in the treatment of lung cancer / 中华肿瘤杂志

ABSTRACT

<p><b>OBJECTIVE</b>To discuss the therapeutic effect and toxicity of second line Hycamtin for lung cancer patients.</p><p><b>METHODS</b>Ten of these 21 patients had been treated with operation. All these 21 patients received second line Hycamtin treatment; given at the dose of 1.2 mg/m(2) per day, four consecutive days as one cycle and 21 days as one course. A total of 1 - 4 courses were given according to the patient's tolerance. Four of these 21 patients also received combination of cisplatin.</p><p><b>RESULTS</b>Among the 13 un-operated patients, two patients showed CR, six showed PR, three SD and two PD, giving an effective rate of 62%. Among the 8 operated patients, seven showed SD but one developed distant metastasis. The 1-year survival rate was 88%.</p><p><b>TOXICITY</b>leukopenia I-II degree 14 (66.7%), leukopenia III-IV degree 5 (23.8%), thrombocytopenia III-IV degree 1 (4.8%) and one patient died of high fever and neutocytopenia. Nausea 8 (38.1%), vomiting 3 (14.3%) and diarrhea 2 (9.5%) alopecia 4 (19.1%). Were the other side-effects.</p><p><b>CONCLUSION</b>Hycamtin is indicated for second line therapy for lung cancer giving tolerable toxicity.</p>